Logo

Myriad

Myriad Genetics Recalibrates Breast Cancer PRS for All Ancestries in Anticipation of Broader Launch
Premium

At ASCO, the company detailed its efforts to make the 93-SNP riskScore, which it plans to offer as a standalone DTC test next year, relevant for women of all ancestries.

In Brief This Week: Oncocyte, Qiagen, Myriad Genetics, Iaso Biotherapeutics

News items for the week of May 31, 2021. 

Castle Biosciences Acquires Myriad Genetics' MyPath Melanoma Test, Lab for $32.5M

The sale, part of Myriad's planned strategic refocusing of its business, will allow Castle to bolster its pipeline of tests for dermatologic cancers.

In Brief This Week: Mirati Therapeutics, Gilead, Natera, Actinium Pharmaceuticals, Myriad Genetics

News items for the week of March 22, 2021. 

Intermountain Gets National Stage, Myriad Adds Tumor Profiling Panel With Combined Test Offering
Premium

Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.

Mar 2, 2021

Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

Jan 22, 2021

In Brief This Week: Myriad Genetics, Diaceutics, Agios, Precipio, Lantern Pharma, Guardant Health

Jan 12, 2021

JP Morgan Healthcare, Day 1: Merck KGaA, Mirati, Agios, Tempus, Bristol Myers, Amgen, and More

Jan 11, 2021

Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan

Jan 8, 2021

In Brief This Week: Genentech, Myriad Genetics, Merus, Ambrx, and More

Dec 9, 2020

Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project

Nov 16, 2020

Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China

Oct 15, 2020

Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests

Jul 31, 2020

Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications

Jul 1, 2020

Polygenic Risk Score Modifies Breast Cancer Risk in Pathogenic Variant Carriers

Jun 4, 2020

PARP Inhibitor Response Markers Still Key Consideration in Ovarian Cancer Despite Broad Indications
Premium

May 31, 2020

Polygenic Risk Score, Family History Refine Breast Cancer Risk Assessment in CHEK2 Mutation Carriers

May 20, 2020

FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer

May 14, 2020

AstraZeneca's Lynparza Gives Survival Boost as Maintenance in Relapsed BRCA-Mutated Ovarian Cancer

May 11, 2020

FDA Approves Lynparza/Avastin With Myriad Genetics CDx for Platinum-Sensitive Ovarian Cancer

Apr 30, 2020

GSK Gets Broad Zejula Indication in Ovarian Cancer; FDA Deems Myriad Genetics' Test Complementary

Apr 29, 2020

EMBRACA Trial Shows No Overall Survival Difference Between Talzenna, Chemotherapy Arms

Apr 6, 2020

Myriad Genetics BRCA Test to be Reimbursed in Japan

Apr 2, 2020

Full BRCA1 Gene Deletion Suspected to Contribute to Patient's Long PARP Inhibitor Response
Premium

Mar 30, 2020

Myriad Genetics Seeks Japan Approval for Advanced Pancreatic, Prostate Cancer Companion Diagnostic